Novonesis (Novozymes) A/S (CO:NSIS-B) — Stock Price

Dkr421.00 DKK
▼ -1.38% today

Novonesis (Novozymes) A/S (CO:NSIS-B) is currently trading at Dkr421.00 DKK, down 1.38% today. Over the past 52 weeks, shares have ranged between Dkr342.00 and Dkr429.20. This page tracks Novonesis (Novozymes) A/S's live share price on the CO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NSIS-B market cap overview.

Novonesis (Novozymes) A/S (NSIS-B) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Novonesis (Novozymes) A/S's daily closing share price and trading volume on the CO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Novonesis (Novozymes) A/S Income Statement — Revenue, Profit & Earnings by Year

Novonesis (Novozymes) A/S's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Dkr4.15 Billion Dkr3.83 Billion Dkr17.90 Billion Dkr2.36 Billion Dkr14.95 Billion
Cost of Revenue Dkr1.91 Billion Dkr2.02 Billion Dkr8.18 Billion Dkr1.07 Billion Dkr6.31 Billion
Gross Profit Dkr2.24 Billion Dkr1.81 Billion Dkr9.72 Billion Dkr1.29 Billion Dkr1.16 Billion
Research & Development Dkr463.45 Million Dkr412.88 Million Dkr2.02 Billion Dkr268.56 Million Dkr2.01 Billion
SG&A Dkr223.03 Million Dkr214.43 Million Dkr958.91 Million Dkr127.77 Million Dkr859.00 Million
Total Operating Expenses Dkr1.36 Billion Dkr1.15 Billion Dkr5.17 Billion Dkr664.08 Million Dkr4.74 Billion
Operating Income Dkr881.93 Million Dkr658.48 Million Dkr4.55 Billion Dkr621.27 Million Dkr4.01 Billion
EBITDA Dkr1.39 Billion Dkr1.04 Billion Dkr5.47 Billion Dkr820.71 Million Dkr5.40 Billion
EBIT Dkr811.09 Million Dkr493.11 Million Dkr4.08 Billion Dkr625.16 Million Dkr4.03 Billion
Interest Expense Dkr80.47 Million Dkr87.55 Million Dkr223.00 Million Dkr158.00 Million Dkr102.00 Million
Income Before Tax Dkr742.84 Million Dkr416.77 Million Dkr3.91 Billion Dkr611.47 Million Dkr3.92 Billion
Income Tax Expense Dkr159.68 Million Dkr111.21 Million Dkr870.25 Million Dkr116.76 Million Dkr779.00 Million
Net Income Dkr583.16 Million Dkr305.56 Million Dkr3.02 Billion Dkr493.36 Million Dkr3.15 Billion

Novonesis (Novozymes) A/S Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Novonesis (Novozymes) A/S's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Dkr16.35 Billion Dkr15.20 Billion Dkr28.39 Billion Dkr27.98 Billion Dkr24.77 Billion
Total Current Assets Dkr1.98 Billion Dkr1.88 Billion Dkr9.46 Billion Dkr9.24 Billion Dkr7.82 Billion
Cash & Equivalents — — — — —
Short-term Investments Dkr20.30 Million Dkr4.00 Million Dkr40.00 Million Dkr80.00 Million Dkr75.00 Million
Net Receivables Dkr869.40 Million Dkr804.60 Million Dkr543.50 Million Dkr3.60 Billion Dkr2.99 Billion
Inventory Dkr772.20 Million Dkr720.60 Million Dkr3.63 Billion Dkr3.80 Billion Dkr2.99 Billion
Property, Plant & Equipment — — — Dkr12.07 Billion Dkr10.19 Billion
Goodwill Dkr6.19 Billion Dkr5.61 Billion Dkr1.98 Billion Dkr2.01 Billion Dkr2.02 Billion
Total Liabilities Dkr5.49 Billion Dkr4.02 Billion Dkr14.04 Billion Dkr13.76 Billion Dkr12.56 Billion
Total Current Liabilities Dkr2.74 Billion Dkr1.09 Billion Dkr7.26 Billion Dkr6.96 Billion Dkr5.67 Billion
Long-term Debt — Dkr1.53 Billion Dkr4.33 Billion Dkr3.62 Billion Dkr494.40 Million
Net Debt Dkr22.17 Billion Dkr1.52 Billion Dkr6.62 Billion Dkr5.81 Billion Dkr-481.00 Million
Total Stockholder Equity Dkr10.86 Billion Dkr11.18 Billion Dkr13.98 Billion Dkr13.84 Billion Dkr11.83 Billion
Retained Earnings Dkr11.16 Billion Dkr11.03 Billion Dkr13.76 Billion Dkr13.06 Billion Dkr11.30 Billion

Novonesis (Novozymes) A/S Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Novonesis (Novozymes) A/S generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Dkr1.22 Billion Dkr1.02 Billion Dkr4.15 Billion Dkr4.01 Billion Dkr4.06 Billion
Capital Expenditures Dkr470.80 Million Dkr359.80 Million Dkr2.06 Billion Dkr2.89 Billion Dkr1.24 Billion
Free Cash Flow Dkr750.70 Million Dkr660.10 Million Dkr2.10 Billion Dkr1.12 Billion Dkr2.82 Billion
Investing Cash Flow Dkr-1.97 Billion Dkr-199.70 Million Dkr-2.13 Billion Dkr-2.67 Billion Dkr-2.75 Billion
Financing Cash Flow Dkr753.30 Million Dkr-703.20 Million Dkr-1.89 Billion Dkr-1.25 Billion Dkr-1.59 Billion
Dividends Paid Dkr402.70 Million Dkr249.80 Million Dkr2.86 Billion Dkr1.52 Billion Dkr1.47 Billion
Stock-Based Compensation Dkr20.40 Million Dkr28.80 Million Dkr20.28 Million Dkr127.00 Million Dkr78.00 Million
Depreciation Dkr574.80 Million Dkr544.10 Million Dkr1.39 Billion Dkr1.46 Billion Dkr1.37 Billion
Change in Cash Dkr-4.70 Million Dkr130.30 Million Dkr75.00 Million Dkr78.00 Million Dkr-218.00 Million

Novonesis (Novozymes) A/S Earnings History — EPS Actual vs. Analyst Estimates

Track Novonesis (Novozymes) A/S's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Aug 20, 2026 — — —
May 05, 2026 4.26 4.16 +2.31%
Feb 24, 2026 3.36 7.15 -53.01%
Nov 06, 2025 3.06 4.65 -34.24%
Aug 21, 2025 2.69 3.73 -27.88%
May 08, 2025 3.14 2.92 +7.53%
Feb 26, 2025 1.38 2.68 -48.61%
Nov 07, 2024 2.50 3.96 -36.86%